Compare Enveric Biosciences Inc (ENVB) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Sony Group Corp — how do they compare? Enveric Biosciences Inc trades at $1.36 (market cap $5.32M), while Sony Group Corp trades at $21.23 (market cap $123.02B). The key difference: Sony Group Corp is far larger — about 23124.1× Enveric Biosciences Inc's market cap, and Sony Group Corp pays a 0.76% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | SONY | |
|---|---|---|
Market Cap | $5.32M | $123.02B |
Sector | Health | Technology |
52-Week High | $17.40 | $30.26 |
52-Week Low | $1.28 | $19.32 |
Enterprise Value | $408.82K | $119.51B |
Dividend Yield | — | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Sony trades at $20.80, up 0.58% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong operating cash flow of $2.32 trillion in 2025, but faces a projected net loss in 2026. Analyst consensus is bullish with 68.75% buy ratings, while recent news highlights Sony's strategic shift to digital-only PlayStation games by 2028.
The outlook is mixed: strong cash flow and analyst support provide upside potential, but 2026's projected loss and bearish technicals pose near-term risks. Investors should weigh the digital transition's long-term benefits against execution challenges and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
